Clinical trials: Vaccine Immune Response
Prevention of Zika Infection, Zika-Specific Immune Response
VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults
Background: People get Zika virus from infected mosquitos. They usually don t get very sick. But birth defects were reported in babies born to mothers who had Zika infection.
- Trial name
- NCT02996461
- Testing
- VRC-ZKADNA090-00-VP
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Adult Immune Responses to Vaccine
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Background: Ebola is a virus that has infected and killed people mostly in West Africa. There is no treatment or prevention for it, but several drugs are being studied.
- Trial name
- NCT03478891
- Testing
- VRC-EBOMAB092-00-AB (MAb114)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Respiratory Infection, COVID-19 Vaccine Adverse Reaction
A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine
This is a randomized, placebo-controlled, double-blinded phase I study, designed to evaluate the safety including reactogenicity and immunogenicity of this investigational DNA vaccine delivered intramuscularly by in vivo EP in…
- Trial name
- OpenCorona1 (NCT05685953)
- Testing
- DNA vaccine OC-007
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Matti Sällberg
HIV Infections
Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.
- Trial name
- NCT00071851
- Testing
- VRC-HIVDNA009-00-VP
- Where
- 14 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Aids, Cdc Group I
HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Treatment: Immunization with peptide-mix and adjuvant. The vaccine should induce cellular immunity against HIV-1. Target group: Untreated healthy individuals with chronic HIV-1 infection.
- Trial name
- HIV-BIS (NCT01141205)
- Testing
- AFO-18, Saline
- Where
- 2 sites in Guinea-Bissau
- Volunteers
- 18 people
- Sponsor
- Statens Serum Institut
COVID-19 Vaccination, Inflammation
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
Analysis of humoral antibody and cytokine kinetics after vaccination with either BNT162b2 or ChAdOx1 nCoV-19 vaccine and factors influencing the vaccine immunogenicity
- Conditions
- COVID-19 Vaccination, Inflammation, Vaccine Immune Response, Vaccine Adverse Reaction
- Trial name
- NCT05315856
- Testing
- either BNT162b2 or ChAdOx1 vaccine
- Where
- 3 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Korea University Guro Hospital
Iron Deficiency Anemia
Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women
Iron deficiency (ID) anemia (IDA) is a global public health problem, with the highest prevalence in Africa. Vaccines often underperform in low- and middle- income countries (LMIC), and undernutrition, including ID, likely plays a…
- Trial name
- NCT05919472
- Testing
- Oral iron supplementation (pre-treatment), COVID-19 vaccine, MenACWY vaccine
- Where
- Kenya
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Nicole Stoffel
West Nile Fever
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults
West Nile (WN) virus infection is an emerging disease. Infection with WN virus may lead to paralysis, coma, and death. The purpose of this study is to determine the safety of and immune response to a two-dose regimen of a WN…
- Trial name
- NCT00537147
- Testing
- WN/DEN4delta30 vaccine
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an…
- Trial name
- NCT06740630
- Testing
- Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3
- Where
- 97 sites in United States, Belgium and 9 more
- Volunteers
- 1,840 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important…
- Trial name
- NCT03028987
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
This randomized, placebo-controlled, double-blind, safety and dose-finding Phase Ia trial will evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a…
- Trial name
- NCT05537038
- Testing
- BNT164a1, BNT164b1
- Where
- 3 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05329038
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19, Solid Tumor
National Project on Vaccines, COVID-19 and Frail Patients
This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence…
- Conditions
- COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder
- Trial name
- VAX4FRAIL (NCT04848493)
- Testing
- COVID-19 vaccines
- Where
- 12 sites in Italy
- Volunteers
- 747 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Smallpox
Human Immune Responses Smallpox
The purpose of this study is to attempt to identify the immune response of healthy adults to an investigational dilution of the Dryvax smallpox vaccine.
- Trial name
- NCT00068198
- Testing
- Dryvax
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- PROSECO (NCT04858568)
- Where
- 9 sites in United Kingdom
- Volunteers
- 592 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Immune Response to Oral Polio Vaccine
A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals
Bilthoven Biologicals has developed a new bivalent oral polio vaccine (bOPV) containing World Health Organization (WHO) approved Sabin strains of poliovirus type 1 and type 3.
- Trial name
- NCT02766816
- Testing
- Part 1 study - BBio bOPV, Part 2 study - BBio bOPV Lot 1, Part 2 study - BBio bOPV Lot 2
- Where
- Bangladesh
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Bilthoven Biologicals
Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine
After immunization, particularly in older persons, some people are protected from disease by a vaccine and others are not. The investigators believe that this variable response may be due to overproduction of molecules that…
- Trial name
- NCT01288014
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Columbia University
Influenza, Human
Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.
This is a prospective, Open label randomized study. A total of 220 adults aged ≥ 60 years will be enrolled and randomized to one of 2 study arms: 1.
- Trial name
- NCT02101749
- Testing
- trivalent inactivated influenza
- Where
- Thailand
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lymphoma, Multiple Myeloma
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
Primary objective 1) To assess whether oncologic and hematologic patients develop a protective immunological response after pandemic Influenza A (H1N1) vaccine Secondary objectives 1.
- Conditions
- Lymphoma, Multiple Myeloma, Myeloproliferative Disease
- Trial name
- NCT01394640
- Testing
- Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
- Where
- Italy
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Paolo Corradini